A SINGLE-BLIND, RANDOMIZED, ESCALATING MULTIPLE DOSE STUDY (PART 1) AND A SEVEN TREATMENT CROSSOVER BIOAVAILABILITY STUDY (PART 2) OF LT-NS001 AND NAPROXEN ADMINISTERED IN HEALTHY SUBJECTS

A SINGLE-BLIND, RANDOMIZED, ESCALATING MULTIPLE DOSE STUDY (PART 1) AND A SEVEN TREATMENT CROSSOVER BIOAVAILABILITY STUDY (PART 2) OF LT-NS001 AND NAPROXEN ADMINISTERED IN HEALTHY SUBJECTS - LT-NS001 escalating multiple dose and bioavailability study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON31529

Enrollment

Registered

2007-11-16

Start date

2008-11-21

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronische pijn zoals bij Rheumatische arthritis Chronic pain

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy subjects Male, 18-70, inclusive (Part 1) Male/Female, 45-70, inclusive(Part 2), famales must be post menopausal

Exclusion criteria

Exclusion criteria: Pathology for example Hepatitis B, Cancer or HIV/AIDS. If you have participated in any other drug investigation within 90 days preceding the start of this study or if you have donated blood within 60 days preceding start of this study or loss of blood of similar volume.

Design outcomes

Primary

Measure	Time frame
-	—

Secondary

Measure	Time frame
-	—

Countries

Netherlands

Outcome results